HCW Biologics Inc.

HCWB

US40423R1059

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-22 pm EDT			5-day change	1st Jan Change
1.63 ^USD	+6.54%		+0.62%	+33.06%

Apr. 01	HCW Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 01	HCW Biologics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

HCW Biologics Inc.(NasdaqGM:HCWB) added to S&P TMI Index

September 20, 2021 at 12:00 am EDT

Latest news about HCW Biologics Inc.

HCW Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
HCW Biologics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Apr. 01	CI
HCW Biologics Inc. announced that it has received $2.500005 million in funding	Feb. 19	CI
HCW Biologics Inc. Exercises Its Right to Terminate Its Credit Agreement	Jan. 12	CI
HCW Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Earnings Flash (HCWB) HCW BIOLOGICS Reports Q3 Revenue $853,102	Nov. 14	MT
HCW Biologics Inc. Announces Results from Preliminary Human Data Readout from an Ongoing Phase 1 Clinical Trial Sponsored by the University of Minnesota	Nov. 08	CI
HCW Biologics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Earnings Flash (HCWB) HCW BIOLOGICS Reports Q2 Revenue $622,807	23-08-11	MT
Hcw Biologics Inc. Announces Appointment of Rick S. Greene as Class II Director	23-06-14	CI
HCW Biologics Says It Received Patent for Methods to Treat Diseases Caused by Chronic Inflammation	23-06-14	MT
EF Hutton Assumes HCW Biologics at Buy With $9 Price Target	23-06-01	MT
HCW Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Hcw Biologics Inc. Secures $26.25 Million Non-Dilutive Financing with Asset-Backed Development Loan	23-04-27	CI
HCW Biologics Inc. announced that it expects to receive $26.25 million in funding	23-04-19	CI
HCW Biologics Inc. Enters Cooperative Research and Development Agreement with National Cancer Institute	22-12-08	CI
JonesTrading Starts HCW Biologics at Buy With $8 Price Target	22-11-08	MT
HCW Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-07	CI
Earnings Flash (HCWB) HCW BIOLOGICS Reports Q3 Revenue $361.8M	22-11-07	MT
HCW Biologics Files $100 Million Mixed Shelf	22-08-22	MT
HCW Biologics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-12	CI
Earnings Flash (HCWB) HCW BIOLOGICS Reports Q2 Revenue $166,800	22-08-12	MT
Earnings Flash (HCWB) HCW BIOLOGICS Reports Q1 Revenue $3.12M	22-05-13	MT
HCW Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13	CI
HCW Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-29	CI

HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions such as long-haul COVID-19. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth factor-Î² and stimulate immune cells, targeting senescent cells and the SASP factors they secrete. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, and others.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.63 USD

Average target price

4 USD

Spread / Average Target

+145.40%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
HCW BIOLOGICS INC.	+33.06%	61.65M
REGENERON PHARMACEUTICALS, INC.	+2.49%	96.73B
ARGENX SE	-0.29%	21.31B
BIONTECH SE	-16.61%	21.21B
GENMAB A/S	-5.52%	18.79B
WUXI APPTEC CO., LTD.	-42.14%	16.37B
BEIGENE, LTD.	-27.40%	13.68B
NEUROCRINE BIOSCIENCES, INC.	+1.44%	13.44B
SAREPTA THERAPEUTICS, INC.	+21.29%	10.98B
LEGEND BIOTECH CORPORATION	-21.79%	8.56B

Bio Therapeutic Drugs